UBS Group
PTCT icon

UBS Group’s PTC Therapeutics PTCT Stock Holding History

UBS Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-33,800
Closed -$2.06M – 9369
2020
Q4 		$2.06M Buy
+33,800
New +$1.99M ﹤0.01% 3384
2017
Q2 		– Sell
-159,200
Closed -$1.57M – 7912
2017
Q1 		$1.57M Buy
+159,200
New +$1.93M ﹤0.01% 3155
2015
Q2 		– Sell
-5,000
Closed -$304K – 8758
2015
Q1 		$304K Buy
+5,000
New +$305K ﹤0.01% 4542

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

UBS Group's PTCT Position: Q1 2026 in Review

UBS Group increased its PTC Therapeutics (PTCT) stake by 41% in Q1 2026, buying an estimated $28.3M and bringing the position to 1,364,768 shares worth $93M. The position accounts for 0.01% of the portfolio, ranked #1108.

UBS Group first reported a position in PTCT in Q4 2014 and has held it in 46 quarters since. 350 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • UBS Group held 1,364,768 shares of PTC Therapeutics worth $93M as of Q1 2026.
  • UBS Group bought 400,110 PTC Therapeutics shares in Q1 2026, an estimated $28.3M.
  • PTC Therapeutics made up 0.01% of UBS Group's portfolio in Q1 2026, its #1108 holding.
  • UBS Group first reported a position in PTC Therapeutics in Q4 2014 and has held it in 46 quarters since.
  • 350 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.